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http://dxObjectives: The present study compared the interval until device exchange or death from pump-related failure
in patients with pulsatile versus continuous flow left ventricular assist devices.
Methods: Data from Interagency Registry for Mechanically Assisted Circulatory Support (June 23, 2006, to
March 31, 2011) compared the durability of implanted pulsatile and continuous flow left ventricular assist
devices. The durability issues included pump replacement for infection, thrombosis-hemolysis, driveline failure,
or pump drive unit failure, and death from driveline or pump drive unit failure.
Results:A total of 3302 left ventricular assist devices were implanted (486 pulsatile, 2816 continuous flow) and
98 pump exchanges or deaths from durability issues (46 pulsatile, 52 continuous flow; 3% of implants). The
interval to device issue was greater for the continuous flow than for the pulsatile devices (P<.001). A compar-
isons of the causes for pump exchange or pump-related death showed (1) greater freedom from pump failure in
the continuous flow compared with the pulsatile left ventricular assist devices (10 events/2816 continuous flow
implants vs 39 events/486 pulsatile implants; P<.0001); (2) similar exchange or pump-related death for drive-
line failure (1/486 pulsatile vs 7/2816 continuous flow; P¼ .82); (3) similar exchange or pump-related death for
thrombosis-hemolysis (2/486 pulsatile vs 28/2816 continuous flow; P¼ .25); and (4) fewer exchanges or pump-
related deaths from infection in continuous flow left ventricular assist devices (4/486 pulsatile vs 7/2816 con-
tinuous flow; P ¼ .034). Competing outcomes analysis corroborated this finding, with 54% of continuous
flow versus 23% of pulsatile patients alive and receiving support at 12 months after implantation.
Conclusions: The Analysis of Interagency Registry for Mechanically Assisted Circulatory Support data showed
greater durability for continuous flow than for pulsatile left ventricular assist devices. Even longer durations of
support can be expected if pump durability continues to improve. (J Thorac Cardiovasc Surg 2013;146:437-41)T
XSupplemental material is available online.
Patients receiving a mechanical circulatory support device
(MCSD) place their lives in the hands of the engineers
who design the MCSDs and the physicians who manage
the MCSDs. From the patient’s standpoint, the ideal
MCSD would have sufficient durability to sustain their
life until they die of something other than heart failure, me-
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The Journal of Thoracic and CaFrom an engineering and clinical perspective, the reli-
ability or durability is measured by the rate of device failure
over time.1 MCSD failure can be the result of a mechanical
problem (eg, drive unit or motor failure of an implanted
ventricular assist device [VAD]) or a biologic complication
involving the MCSD (eg, device thrombosis or hemolysis).
The most devastating failures of durability result in death of
the patient. If MCSD failure is not fatal but requires re-
placement of the implanted components, it exposes the pa-
tient to the important risks of death and other adverse
events.
In the present study, we analyzed the durability of
MCSDs that have been approved by the Federal Food and
Drug Administration (FDA) and tracked by the Interagency
Registry for Mechanically Assisted Circulatory Support
(INTERMACS).2 Our aim was to define the MCSD failure
rates for several modes of failure and to compare the failure
rates and modes of failure for the 2 major classes of
MCSDs: pulsatile and continuous flow (CF) pumps. The ul-
timate goals were to (1) stimulate improvements in the en-
gineering of MCSDs; and (2) suggest changes in the
clinical treatment of patients to maximize MCSD
durability.rdiovascular Surgery c Volume 146, Number 2 437
Abbreviations and Acronyms
CF ¼ continuous flow
FDA ¼ Food and Drug Administration
INTERMACS ¼ Interagency Registry for
Mechanically Assisted Circulatory
Support
LVAD ¼ left ventricular assist device
MCSD ¼ mechanical circulatory support
device
VAD ¼ ventricular assist device
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The INTERMACS is a national registry for patients who receive
a MCSD to treat advanced medically refractory heart failure. The INTER-
MACS indications for mechanical circulatory support include destination
therapy (ie, a long-termMCSD for patients with a contraindication to trans-
plantation), bridge to transplantation, and bridge to recovery of the native
heart. Only FDA-approvedMCSDs that can be used in an outpatient setting
are included in the INTERMACS.2
A total of 106 institutions were enrolled in the INTERMACS from June
23, 2006 to March 31, 2011, the period of data acquisition for the present
study. The data were entered using encryption to a secure server adminis-
tered by the United Network for Organ Sharing. The United Network for
Organ Sharing data repository is accessible to INTERMACS investigators
for analysis of patient de-identified information. The study sites and central
data processing and analyzing facilities received institutional review board
approval before initiating the collection of data. All patients provided in-
formed consent before entry in the INTERMACS. The data were managed
according to the Health Insurance Portability and Accountability Act
regulations.
During this phase of data acquisition, the MCSDs included in the
INTERMACS database included the AbioCor total artificial heart
(Abiomed, Danvers, Mass); the HeartMate IP, VE, and XVE left VADs
(LVADs; Thoratec, Pleasanton, Calif); the HeartMate II LVAD (Thoratec),
the MicroMed DeBakey Child LVAD (MicroMed, Houston, Tex); the
Novacor PC and PCq LVADs (Novacor, Oakland, Calif); the SynCardia
Cardiowest total artificial heart (Syncardia Systems, Tucson, Ariz); and
the Thoratec implantable VAD and paracorporeal VAD pumps (Thoratec,
Pleasanton, Calif).3 The total artificial hearts and paracorporeal VADs
were not included in the present analysis. Only adults aged 18 years or
older were included in the present study; thus, the MicroMed DeBakey
Child LVADs were excluded.
The INTERMACS variables describing the preimplant demographic
profile, indication for mechanical circulatory support, and clinical variables
that described the preimplant patient condition, hemodynamics, and labo-
ratory values were analyzed to define the risk factors for postoperative de-
vice durability. The relevant durability issues included pump replacement
for intractable infection, thrombosis-hemolysis, driveline failure, or pump
drive unit failure and death from driveline or pump drive unit failure. The
patients were censored from the analysis because of transplantation, device
removal for recovery, and death not related to pump failure.
The INTERMACS data were checked for completeness by the central
collection facility (United Network for Organ Sharing). The data that
were outside the predetermined limits were validated by their site of origin;
however, the source documents were not routinely checked against the data
submitted to the INTERMACS. The adverse event forms were reviewed by
physician volunteers from the INTERMACS community and checked fur-
ther by the members of the INTERMACS adverse event committee before
a final adjudication was made on the individual adverse events.438 The Journal of Thoracic and Cardiovascular SurgThe variables describing the preimplant patient condition, indication for
mechanical circulatory support, demographic profile, hemodynamics, lab-
oratory values, and durability issues were gathered. The data were analyzed
using a competing outcomes method to identify the risk factors for postop-
erative pump exchange and death from durability issues. The pulsatile and
CF rotary pumps were compared for durability as an aggregate outcome
and were compared again according to the individual durability issues
specified in the previous paragraphs.
RESULTS
The data for 3302 patients were entered by 106 institu-
tionswithin the study period, with a follow-up date ofMarch
31, 2011. Pulsatile pumps were approved for clinical use by
the Federal FDA before CF pumps; therefore, these 2 groups
were nonconcurrent. Of the 3302 LVADs implanted, 486
were pulsatile and 2816 were CF LVADs. The total experi-
ence included 2624 patient-years of support and 585 non–
pump-related deaths. Also, 100 pump exchanges occurred
and 11 deaths from durability issues (59 pulsatile deaths/ex-
changes and 52 CF deaths/exchanges; Table 1). The pump-
related issues that led to exchange or death are listed in Table
E1, and the interval to device issue (pump exchange or
pump-related death) is shown in Figure 1. The CF devices
failed predominantly because of pump thrombosis and he-
molysis (28/52 [54% of events]), and the pulsatile pump
failed predominantly because of pump drive unit failure
(46/59 [78% of events]). The interval to all-cause pump-re-
lated failure (death or pump exchange) was significantly
(P<.0001) longer for CF pumps than for pulsatile pumps.
The causes for durability failure are depicted individually
in Figures 2, 3, E1, and E2. The durability, as defined by
drive unit failure, was significantly better for the CF pumps
than the pulsatile pumps (P<.0001; Figure 2). The interval
to the first driveline problem, thrombosis-hemolysis, or in-
fection that required device exchange was similar for the
pulsatile and CF LVADs (Figures 3, E1, and E2). The com-
peting outcomes analyses for pulsatile and CF pumps
(Figure 4) corroborate the greater durability of CF pumps
compared with pulsatile pumps. This was evidenced by
the greater proportion of CF patients remaining on pump
support at 12 months after device implant (54% of 2816
CF implants vs 32% of 486 pulsatile LVADs), although
other possible explanations exist for the finding. Other ex-
planations include a greater proportion of patients with
panel reactive antibodies or blood group O or a greater num-
ber of destination therapy patients than bridge to transplan-
tation patients in the CF group.
DISCUSSION
The concept of durability is of obvious importance to car-
diac replacement therapies. In 1998, a joint American Soci-
ety for Artificial Internal Organs–Society of Thoracic
Surgeons committee published recommendations and goals
for the development and clinical evaluation of MCSDs.4
That document defined failure as ‘‘the termination of theery c August 2013
TABLE 1. Reasons for pump exchange or device-related problem that
contributed to patient death stratified by pump type (pulsatile vs
continuous flow)
Outcome
Pump type
Continuous flow
Pulsatile
intracorporeal flow
Dead 424 (15.06) 171 (35.19)
Non–pump related 420 (14.91) 164 (33.74)
Pump related
Thrombosis/hemolysis 3 (0.11) 2 (0.41)
Drive line 1 (0.04) 0 (0.00)
Drive unit 0 (0.00) 5 (1.03)
Transplant 809 (28.73) 247 (50.82)
Recovery 19 (0.67) 12 (2.47)
Device exchange 48 (1.70) 52 (10.70)
Infection 7 (0.25) 4 (0.82)
Pump related
Thrombosis/hemolysis 25 (0.89) 6 (1.23)
Drive line 6 (0.21) 1 (0.21)
Drive unit 10 (0.35) 41 (8.44)
Alive 1516 (53.84) 4 (0.82)
Total 2816 (100) 486 (100)
Data presented as n (%).
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Event:  Device Exchange/Death related to device issue
(censored at death, transplantation, recovery)
Pulsatile intracorporeal = 486
Drive Unit Pump Issues=41
Continuous Flow= 2816
Drive Unit Pump Issues=10
p < 0.0001
FIGURE 2. Deaths and device exchanges from drive unit failure are
shown for pulsatile and continuous flow ventricular assist devices
(P<.0001; pulsatile vs continuous flow ventricular assist devices).
Holman et al Cardiothoracic Transplantationability of an item to perform a required function or the in-
ability of the device or any of its components to meet perfor-
mance specifications.’’4 The committee also suggested
metrics for reliability based on in vitro testing (eg, mock cir-
culation loop), animal device implants, and clinical trials
(eg, investigational device exemption trials). The present
analysis had a somewhat different perspective on device
failure because we only used data gathered from the post-
marketing surveillance of FDA-approved MCSDs5 and in-
cluded modes of failure that might not be discovered in
animal trials (eg, device exchange because of intractableTime to Device Issue (Exchanged or Contributed to Death)
Months after Device Implant
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Event:  Device Exchange/Death related to device issue
(censored at death, transplantation, recovery)
Pulsatile intracorporeal = 486
Device exchanges=52
Continuous Flow= 2816
Device exchanges=52
p < 0.0001
FIGURE 1. The intervals to device exchange or device-related death for
all causes are depicted for pulsatile and continuous flow ventricular
assist devices (P< .0001; pulsatile vs continuous flow ventricular assist
devices).
The Journal of Thoracic and Cadevice-related infection). These postmarketing surveillance
data were gathered by the INTERMACS, a collaborative ef-
fort of physicians, industry, the National Institutes of
Health, the FDA, and the Centers for Medicare and Medic-
aid Services.6,7
The INTERMACS captures the vast majority of LVAD
implants in North America. The data entered at the individ-
ual sites are checked by the INTERMACS, although not to
the extent of an investigational device exemption trial. The
INTERMACS does not include data from MCSDs that are
in clinical trials. Therefore, no centrifugal design rotary
pump (eg, HeartWare LVAD; HeartWare International, Fra-
mingham,Mass) has been represented in the INTERMACS.
Despite these limitations, the INTERMACS provides theFIGURE 3. Interval to device exchange or patient death from intractable
device-related infection is depicted for pulsatile and continuous flow ven-
tricular assist devices (P<.0363; pulsatile vs continuous flow ventricular
assist devices).
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FIGURE 4. A, Competing outcomes (cardiac transplantation, death, survival onmechanical circulatory support device, and recovery of the native heart) for
patients with continuous flow ventricular assist devices. B, Competing outcomes (cardiac transplantation, death, survival on mechanical circulatory support
device, and recovery of the native heart) for patients with pulsatile ventricular assist devices.
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comes of patients supported by MCSDs.5,8
Device durability is extremely important to MCSD pa-
tients and their physicians. Device failure for any reason
typically requires pump replacement, which adds substan-
tial cost to MCSD therapy, exposes the patient to possible
death or morbid events, and diminishes the patient’s quality
of life. The present report was designed to measure the fail-
ure rates for implanted LVADs and to compare these rates
between pulsatile and CF pumps.
Pulsatile LVADs were represented in the INTERMACS
predominantly by the pulsatile HeartMate I (Thoratec).
Moreover, the Randomized Evaluation of Mechanical
Assistance for the Treatment of Congestive Heart Failure
(REMATCH) trial used the HeartMate I for the MCSD arm
of the study, which compared survival and other outcomes
for patients with end-stage heart disease treated with optimal
medical management versus mechanical circulatory support
using a pump approved by the FDA.9 That landmark trial
demonstrated the superiority of mechanical circulatory
support over medical management in patients with severe
heart failure; however, it also illustrated the drawbacks of
mechanical circulatory support. These included substantial
postimplant mortality for LVAD patients at 1 (48%) and 2
(77%) years and a high rate of pump replacement for
pump failure 12 to 18 months after implantation.
The Investigation of Nontransplant-Eligible Patients
Who Are Inotrope Dependent (INTrEPID) trial compared
the pulsatile Novacor LVAD (WorldHeart, Oakland, Calif)
and optimal medical therapy for inotrope-dependent pa-
tients with New York Heart Association functional class
IV symptoms. The INTrEPID trial was a nonrandomized440 The Journal of Thoracic and Cardiovascular Surgstudy that corroborated the superiority of MCSD over med-
ical therapy using a pulsatile LVAD.10 The patients in the
LVAD arm of that study had a 27% 12-month survival,
and mechanical failure of the Novacor LVAD was not listed
as a cause of death or an adverse event for any patient. In the
present trial, cerebrovascular accidents (10/37 patients), in-
fection (7/37 patients), and cardiac dysfunction (5/37 pa-
tients) were the most commonly reported causes of death.
The results of clinical trials stimulated design changes in
pulsatile pumps that resulted in improved patient outcomes,
defined as improved survival with fewer adverse events.11,12
However, the disadvantages of pulsatile implantable blood
pumps compared with implanted rotary CF pumps (eg,
patient acceptance, ease of implantation) resulted in
dominance of the field by CF designs. From the data from
the present study, the durability of CF pumps compared
with pulsatile pumps is an important aspect of the CF
pump advantage. The importance of improved durability
was noted in the first FDA investigational device
exemption trial that compared an axial flow rotary pump
to a pulsatile design.13 The INTERMACS data were used
in the present analysis to quantify the improved durability
of rotary pumps from experience at multiple centers.
Despite the improved durability of CF LVADs, the present
analysis identified problems with the CF designs that led to
pump failure, defined as pump-related adverse events caus-
ing patient death or requiring pump exchange. Pump throm-
bosis and pump-related hemolysis were identified in 28 of 52
of these instances (54%), and intractable infection, drive unit
failure, and driveline problems were each responsible in
13% to 19% of instances. Importantly, all 4 of these prob-
lems are amenable to improvement through designery c August 2013
Holman et al Cardiothoracic Transplantationoptimization by engineers (eg, improved hemocompatibility
of blood contacting materials; diminished turbulence, and
shear forceswithin the pump) or changes in patient treatment
(eg, patient-specific anticoagulation14,15; novel methods for
driveline implantation and stabilization; implementation
of an intensive surveillance protocol for out-patients16).
The clinical results from previous multicenter random-
ized17 and nonrandomized18 studies corroborate the find-
ings of the present analysis regarding the improved
durability of CF LVADs compared with pulsatile LVADs.
In a 2009 study by Pagani and colleagues,18 the 18-month
actuarial survival for the HeartMate II LVAD recipients
was 72% (95% confidence interval, 65%-79%), and in
a 2009 study by Slaughter and colleagues,19 the 24-month
actuarial survival for the HeartMate II LVAD recipients
was 58% (95% confidence interval, 49%-67%).
As investigators identify the features of LVADs that limit
their useful life, subsequent improvements can be expected
that will increase pump durability and patient survival. With
these improvements, it can be expected that survival will
become equivalent between LVAD therapy and heart trans-
plantation for certain patient groups with advanced heart
failure.19 Furthermore, MCSDs might be routinely used be-
fore and after heart transplantation to maximize patient
survival through sequential MCSD and transplantation
therapies.
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FIGURE E1. Deaths and device exchanges from driveline failure are
shown for pulsatile and continuous flow ventricular assist devices
(P<.8218; pulsatile vs continuous flow ventricular assist devices).
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FIGURE E2. Deaths and device exchanges from thrombosis/hemolysis
are shown for pulsatile and continuous flow ventricular assist devices
(P<.2501; pulsatile vs continuous flow ventricular assist devices).
TABLEE1. Possible outcomes for patients supported with ventricular
assist device and reasons for pump exchange or device-related death
Reason
Pump type
Continuous flow
Pulsatile
intracorporeal flow
Infection 7 (13.46) 4 (7.70)
Pump related
Thrombosis/hemolysis 28 (53.85) 6 (11.54)
Drive line 7 (13.46) 1 (1.92)
Drive unit 10 (19.23) 41 (78.85)
Total 52 (100) 52 (100)
Data presented as n (%).
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